Evidence map›Paper›PMID 39207632›Full record

ArticleDiscover oncology2024

Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer.

Ying He, Aili Zhai, Kaiyun Qin, Xin Zhou, Yu Yu, Zhengmao Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying HeDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Aili ZhaiDepartment of Gynecology, Bao Ding No.1 Central Hospital, Baoding, 071000, Hebei , China.
Kaiyun QinDepartment of Gynecology, Hebei General Hospital, Shijiazhuang, 050000, Hebei, China.
Xin ZhouDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Yu YuDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Zhengmao ZhangDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China. zhangzhengmao@hbmu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe current research aims to evaluate the efficacy and safety of anlotinib, an orally administered small-molecular tyrosine kinase inhibitor (TKI), in the treatment of recurrent epithelial ovarian cancer (EOC).

methodsPatients with recurrent EOC subjected to treatment with anlotinib in Fourth Hospital of Hebei Medical University from 2020 to 2022 were included. The evaluation involved a thorough review of medical records, focusing on parameters such as the objective response rate (ORR), disease control rate (DCR), survival outcomes, and safety profile.

resultsThis study recorded 51 patients, with 26 patients undergoing anlotinib monotherapy. The median progression-free survival (PFS) was 4.0 months, whereas the median overall survival (OS) was not reached. Seven cases underwent a combined treatment of anlotinib with chemotherapy. Among them, two patients achieved partial response (PR), two were categorized as stable disease (SD), and three were identified as having progressive disease (PD). The ORR and DCR were 28.5% (2/7) and 57.1% (4/7), respectively. Additionally, 18 cases received anlotinib maintenance therapy, and the median PFS and the median OS were 7.0 months and 25.5 months, respectively. The most prevalent adverse effects included fatigue (38.6%), hypertension (27.3%), nausea and vomiting (25.0%) and hand-foot syndrome (25.0%).

conclusionAnlotinib demonstrated mild efficacy in the treatment of recurrent EOC, whether employed as monotherapy, chemotherapy-combined therapy, or maintenance therapy. The safety profile was proven manageable and well-tolerated, suggesting that anlotinib may emerge as a viable and novel treatment option for recurrent EOC.

Indexed as

AnlotinibDCRORRRecurrent epithelial ovarian cancerSurvival

Identifiers

PMID39207632
PMCPMC11362443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.